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Abstract  
BACKGROUND: Oral lichen planus (OLP) is a chronic inflammatory disease that causes bilateral 
white striations, papules, or plaques on the buccal mucosa, tongue, and gingivae. Erythema, 
erosions, and blisters may or may not be present. Several empirical therapies have been used in 
the treatment of (OLP). 
OBJECTIVE: To evaluate the effect of low level laser therapy (LLLT) versus topical steroids for the 
treatment of erosive-atrophic lichen planus.  
SUBJECTS AND METHODS: Twenty-four patients with erosive-atrophic (OLP) were categorized 
into two groups. In the first group patients were treated with 970 nm diode laser irradiation, while, in 
the second group patients used topical corticosteroids (0.1% triamcinolone acetonide orabase). The 
gender, medical history and pain score were recorded. The pain score was measured before and 
after treatment by visual analogue scale (VAS).  
RESULTS: Steroid-treated group (0.1% triamcinolone acetonide orabase) show reduced pain score 
than laser group.  
CONCLUSION: Topical steroids are more effective than LLLT. LLLT may be used as an alternative 
treatment for symptomatic OLP when steroids are contraindicated. 
 
 
 
 
 
 
Introduction 
 
Oral lichen planus (OLP) is relatively common 
chronic dermatologic disease often affecting oral 
mucosa [1]. OLP is reported (0.5-2.2%) of population 
with peak incidence in (30-60 years) with female 
predominance of (2:1) [1]. OLP involves a cell-
mediated immunologically induced degeneration of 
basal cell layer of epithelium [1].The basic two types 
of lesion occur: totally white (keratotic) and white 
(keratotic) with red (atrophic, erosive, bullous) [2]. 
Keratotic lesions are asmyptomatic with no need of 
therapy, while red lesions patient feel soreness and 
need treatment, as well as their liability for malignant 
transformation [3].  
Squamous cell carcinoma in most cases 
ranges from (0.4-2%) [4]. OLP are usually seen on the 
buccal mucosa, less common on the tongue, inner 
aspect of the lips and gingival [5]. Numerous 
treatment options of (OLP) include topical and 
systemic agents [6]. As OLP is immunologically 
mediated condition, corticosteroids are recommended. 
Topical corticosteroids abide the mainstay of therapy, 
and are widely accepted as the primary treatment of 
choice [7].  
Topical corticosteroids are the main treatment 
with outcomes in remission and pain/soreness relief 
[8]. The greatest disadvantage of topical therapy for 
symptomatic OLP lesions, include mucosal atrophy, 
candidiasis, adrenal suppression, hypertension, 
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gastrointestinal upset and hyperglycemia [9]. 
Considering the resistance to topical steroids in some 
patients and its disadvantages, other alternative 
effective treatment with minimal side effects seem to 
be vital [10]. Recently, low-level laser therapy (LLLT) 
has been used for treating erosive OLP with minimal 
side effects [11]. 
The Aim of this study was to compare the 
effect of low-level laser therapy (LLLT) (970 nm diode 
laser) versus topical corticosteroids in the treatment of 
symptomatic OLP. 
 
 
Patients and Methods 
 
The study included twenty-four patients (18 
females,6 males) with age range from (35-70 years) 
recruited from outpatient clinic of Oral Medicine and 
Periodontology Department, Faculty of Oral and 
Dental Medicine, Cairo University. Patients included in 
the study with proven diagnosis of OLP based on the 
basis of WHO (World Health Organization) criteria 
(Kramer et al.,1978) [13]. Patients excluded from the 
study were smokers, pregnant and lactating ladies, 
patients under topical and systemic steroids during 
the last two months and uncontrolled diabetic patients 
or hypertension or with positive HCV Ab were also 
excluded. Medical data were collected from the 
patients according to questionnaire of Modified Cornel 
Medical Index (Brightman, 2003) [14]. The study 
protocol was approved by Ethical Committee of the 
Faculty of Oral and Dental Medicine, Cairo University. 
An informed consent was obtained from each patient 
before treatment.  
All participants in both groups undergo oral 
hygiene instructions with complete removal of plaque 
and calculus as they implement intraoral inflammation 
and intensify both extension and symptoms of OLP 
lesions. Patients were advised to avoid accidental 
trauma on soft tissues using soft bristles toothbrush. 
Acidic, spicy, hard, hot food and beverages are 
avoided. The patients were categorized into two 
groups: first group: 12 patients were subjected to laser 
sessions twice weekly with 970 nm diode laser 
(Sirona Dental Laser System GmbH 2005 -2008 
(Fabrikstraβe 31 64625 Bensheim Germany). The 
second group: 12 patients treated with topical 
corticosteroids (0.1% triamcinolone acetonide 
orabase). All cases in both groups are assessed using 
visual analogue scale (VAS) to graduate the severity 
of patients’ pain ranging from 0 (no pain) to 10 
(extreme pain) (Cafaro, et al., 2014) [12] before, 
during and after both treatments. In the laser 
irradiation group the exposure time was 8.0 minutes in 
four successive applications for two minutes each, the 
exposure power setting was (3.0 watt), frequency (30 
hertz). The patients were treated with diode laser in a 
continuous non-contact mode with (320 µm) diameter 
fiber optic as delivery system that was directed at the 
affected areas with defocused mode and overlapping 
exposure until blanching of the treated area had 
occurred. The laser therapy was in the form of two 
sessions weekly for two months with maximum of ten 
sessions. After each laser session patients were 
advised for cold application to prevent edema. 
Oralcure® gel was used postoperatively. Patients in 
the steroid group were treated by topical corticosteroid 
(0.1% topical triamcinolone acetonide preparation). 
This treatment was repeated four times per day for 
four weeks and patients were followed up weekly 
during this period. 
 
Statistical Analysis 
Numerical data were explored for normality by 
checking the distribution of data, calculating the mean 
and median values as well as using tests of normality 
(Kolmogorov-Smirnov and Shapiro-Wilk tests). Data 
were presented as mean and standard deviation (SD) 
values. For parametric data; Student’s t-test was used 
to compare between the two groups. For non-
parametric data; Mann-Whitney U test was used to 
compare between the two groups. Wilcoxon signed-
rank test was used to compare between pre- and 
post-treatment values in each group. Friedman’s test 
was used to compare between pre-, post-treatment 
and after exacerbation values in each group. Wilcoxon 
signed-rank test was used for pair-wise comparisons 
when Friedman’s test is significant. Bonferroni’s 
correction was applied for the pair-wise comparisons. 
Qualitative data were presented as 
frequencies (n) and percentages (%). Chi-square test 
was used to compare between the two groups.  
The significance level was set at P ≤ 0.05. 
Statistical analysis was performed with IBM (IBM 
Corporation, NY, USA), SPSS (SPSS, Inc., an IBM 
Company)
 
 Statistics Version 20 for Windows. 
 
 
Results 
 
No statistically significant difference was 
shown between mean age values and gender 
distributions in the two groups (Table 1). 
Table 1: Mean age values and gender distributions in the two 
groups 
 
Corticosteroids 
(n=12) 
Laser 
(n=12) 
p-value 
Age (Mean, SD) 52.2 (6.4) 53.6 (13.2) 0.766 
Gender (n, %)    
Females 
Males 
10 (83.3) 
2 (16.7) 
9 (75.0) 
3 (25.0) 
0.615 
*: Significant at p ≤ 0.05 
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Medical history 
Seventeen patients were medically free, 2 
were hypertensive, 1 diabetic, and 4 were diabetic 
and hypertensive. There was no statistically significant 
difference between mean medical histories in the two 
groups (Table 2). 
Table 2: Frequencies (n), percentages (%) and results of 
comparison between medical histories in the two groups 
 
Corticosteroids 
(n=12) 
Laser 
(n=12) 
p-value 
n % n %  
Hypertension 0 0.0 2 16.7 
0.255 
Diabetes 0 0.0 1 8.3 
Hypertension and Diabetes 3 25.0 1 8.3 
Free 9 75.0 8 66.7 
*: Significant at p ≤ 0.05 
 
Pain (VAS scores) 
Comparisons between the two groups (pre- 
and post-treatment) have shown that in pre-treatment, 
there was no statistically significant difference 
between the two groups. In the post-treatment, 
Corticosteroids group showed statistically significantly 
lower mean pain scores than Laser group (p = 0.02). 
At follow up, there was no statistically significant 
difference between the two groups (Table 3). 
Table 3: Mean, standard deviation (SD) values and results of 
comparison between pain scores in the two groups 
Time 
Corticosteroids 
(n=12) 
Laser 
(n=12) 
p-value 
Mean SD Mean SD  
    
Pre-treatment 6.8 0.9 7.0 1.8 0.807 
Post-treatment 0.9 1.0 3.9 3.0 0.020* 
Follow up 0.8 1.0 1.5 0.7 0.333 
*: Significant at P ≤ 0.05 
 
Comparison between the Two Groups (after 
exacerbation) 
After exacerbation, there was no statistically 
significant difference between the two groups. 
Table 4: Mean, standard deviation (SD) values and results of 
comparison between pain scores in the two groups after 
exacerbation 
Time 
Corticosteroids 
(n=3) 
Laser 
(n=2) 
p-value 
Mean SD Mean SD  
    
After exacerbation 4.3 2.5 3.5 0.7 0.767 
*: Significant at p ≤ 0.05 
 
In Corticosteroids group as well as laser 
group, there was a statistically significant decrease in 
pain scores post-treatment (p = 0.024, p = 0.043 
respectively). There was no statistically significant 
difference between post-treatment and follow up 
periods; however both showed lower mean pain 
scores than pre-treatment scores. 
 
Table 5: Mean, standard deviation (SD) values and results of 
comparison between pain scores pre- and post-treatment in 
each group 
Time 
Corticosteroids 
(n=12) 
Laser 
(n=12) 
Mean SD Mean SD 
   
Post-treatment 0.9 
b 
1.0 3.9 
b 
3.0 
Follow up 0.8 
b 
1.0 1.5 
b 
0.7 
p-value 0.024* 0.043* 
*: Significant at p ≤ 0.05, Different superscripts in the same column are statistically 
significantly different. 
Figure 1: Line chart representing changes in mean pain (VAS) 
scores in each group 
 
Changes after Treatment in Cases with 
Exacerbation 
In Corticosteroids group as well as Laser 
group, there was a statistically significant decrease in 
pain scores post-treatment. There was a statistically 
significant increase in pain scores after exacerbation; 
however, there was no statistically significant 
difference between pain scores after exacerbation and 
pain scores pre-treatment. 
  
 
Figure 2: Line chart representing changes in mean pain (VAS) 
scores. Pre-, post-treatment and after exacerbation in each group 
 
 
Discussion 
 
OLP is a common chronic dermatologic 
immunological disease; its treatment remains a 
 El Shenawy & Eldin. Low-Level Laser and Topical Steroid Therapies for the Treatment of Erosive-Atrophic Lichen Planus 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2015 Sep 15; 3(3):462-466.                                                                                                                                                                         465 
 
challenge for clinicians. Corticosteroids are the most 
widely accepted treatment for OLP, relieving 
symptoms rather than curing the disease [15]. Various 
treatment regimens are attempted to improve OLP 
lesions, but complete cure has not yet accomplished 
because of its recalcitrant nature [16]. Ţăranu et al., 
2013 [17], stated that OLP frequently occur in patients 
with systemic diseases such as diabetes and 
hypertension. The controlled diabetic patients in the 
study as well as controlled hypertension, undergo 
periodic measurements of blood pressure twice 
weekly, as well as random blood sugar analysis every 
2 weeks were performed to monitor the systemic 
disease. No statistical significant difference in the 
medical condition between two groups (p < 0.253). 
Topical steroids are the most effective treatment with 
promising outcomes in pain/soreness relief [18], and 
are the main treatment for vesiculo-erosive diseases 
of oral mucosa including OLP to reduce pain and 
inflammation [19]. Triamcinolone acetonide used in 
the study showed a satisfactory shelf life and was 
accepted by OLP patients with no complications [20]. 
Topical steroids have common side effects include 
mucosal atrophy, candidiasis, adrenal suppression, 
gastrointestinal upset, hypertension and 
hyperglycemia [21]. Topical steroids have big issue in 
the mouth is making them adherent to oral mucosa for 
sufficient absorption time [22]. LLLT is a new evolution 
in medical/dental treatments, specifically 
mucocutaneous lesions such as symptomatic OLP 
[23]. LLLT accelerate wound healing, anti-
inflammatory effects, increase cellular metabolism, 
modulation of immune system, vasodilatation and 
analgesic effects [24]. The wavelength (970 nm) 
selected to allow superficial action from an optical 
point of view. Exposure time used was 8.0 minutes. 
The laser group of patients assisted 2 sessions 
weekly as recommended by (Jajarm, 2011) [21]. 
Clinical condition is improved in the laser group as 
regard pain (VAS) was apparent after treatment 
showed statistical significant decrease in symptoms (p 
= 0.043) was detected. The results agree with 
statistical significant improvement of (Cafaro, 2014) (p 
= 0.003) [12]. The study show statistical significant 
decrease in pain scores in both treatment categories 
post-treatment. However, topical steroids show lower 
statistical significant mean pain scores than laser 
group (p = 0.02). LLLT possess physiological effects 
include aggregation of prostaglandins (such as PE2), 
immunoglobulins and lymphocytes, as well as beta-
endorphin and encephalin in tissues, resulting in 
reduction of inflammation, immune response and pain 
[25]. 
LLLT recent treatment of OLP (Passeron T, et 
al., 2004) [11], (Trehan M, 2004) [26] and (Taylor CR, 
2004) [26], (Köllner K, et al., 2003) [27] (Mahdavi O et 
al., 2013) [28]. Laser biostimulation obtain intracellular 
biological reactions to stimulate regenerative abilities 
with no side effects (Cafaro, 2014) [12]. No significant 
decrease after exacerbation was detected between 
the two groups. LLLT may be considered as an 
alternative treatment for OLP patients resistant to 
steroids, or those were corticosteroids are 
contraindicated. Although soft laser may not cause 
total relief of symptoms and disappearance of signs, 
but it still improves the patient’s clinical signs and 
symptoms providing positive influence dietary habits 
and quality of life. 
In conclusion, the study demonstrated that 
topical steroid was more effective than LLLT without 
any adverse effects, however LLLT can be considered 
as an alternative treatment for symptomatic OLP in 
coming time and in cases where topical steroids are 
contraindicated. 
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